Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2023
Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional TrialDaniel J Krauss, Theodore Karrison, Alvaro A Martinez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic CancerDaniel V T Catenacci, Melissa R Junttila, Theodore Karrison, et al.
Cancer Biology & Therapy|May 6, 2011
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinomaDaniel V T Catenacci, Gustavo Cervantes, Soheil Yala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2022
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and NeckCherie-Ann O Nathan, D Neil Hayes, Theodore Karrison, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2006
Gene expression profiles in acute myeloid leukemia with common translocations using SAGESanggyu Lee, Jianjun Chen, Guolin Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trialNitin Jain, Emily Curran, Neil M Iyengar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2020
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I TrialJason J Luke, Benjamin E Onderdonk, Sandeep R Bhave, et al.
Pageof 15